NCT05020964UnknownPhase 2
Screening Plasma HER2 Amplication by Digital PCR in Advanced Breast Cancer Patients Treated With Trastuzumab and Pyrotinib
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Enrollment
- 68
- Primary Endpoint
- objective response rate(ORR)
Study Overview
Brief Summary
The hypothesis of this study is to discover the efficacy and safety of trastuzumab combined with pyrotinib in treating advanced breast cancer with HER2 positive, which is detected by digital PCR. It is a single-arm, multicenter phase II clinical study.
The purpose of this study is:
- To explore the Response rate (RR) and progression-free survival(PFS) and safety of patients with recurrent metastatic breast cancer who received trastuzumab combined with pyrotinib in positive plasma HER2 amplification detected by digital PCR.
- To explore the potential using of digital PCR in recurrent and metastatic breast cancer.
Detailed Description
The purpose of this study is:
- To explore the Response rate (RR) and progression-free survival(PFS) and safety of patients with recurrent metastatic breast cancer who received trastuzumab combined with pyrotinib in positive plasma HER2 amplification detected by digital PCR.
- To explore the potential using of digital PCR in recurrent and metastatic breast cancer.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients with recurrent or distant metastatic breast cancer whose primary tissue was negative for HER2 amplification, and newly diagnosed patients with stage IV breast cancer who were negative for HER2 amplification; All enrolled patients had previously received ≥ second-line therapy; Note: ① negative expression of HER2 refers to the primary tissue tested by IHC/FISH (clinical report), and the cell immunohistochemical staining intensity is 0,1 + or 2+, but negative by fluorescence in situ hybridization (FISH).
- •Age range 18-75, female;
- •Good physical strength: ECOG score 0-1;
- •Expected survival of more than 3 months;
- •The patient had no major organ dysfunction;Include: Routine blood The ANC acuity 1.5 x 109 / L;PLT acuity 90 x 109 / L;Hb 90 g/L or higher; Blood biochemical 1.5 x ULN TBIL or less;ALT and AST 2 x ULN or less;ALT and AST≤5×ULN in patients with liver metastases;BUN and Cr≤1.5×ULN and creatinine clearance ≥50 mL/min (Cockcroft-Gault formula); Heart colour to exceed LVEF 50% or higher;Fridericia adjusted QT interval (QTcF) for 12-lead electrocardiogram in men < 450 ms and in women < 470 ms.
- •Evaluable tumor lesions according to RECIST 1.1 criteria;
- •Voluntarily join the group, agree and sign the written informed consent.
Exclusion Criteria
- •Patients who have previously received anti-HER2 therapy, or who have received a study drug or preparation/treatment (i.e., participating in another trial) within 4 weeks prior to enrollment;
- •Patients who are allergic to study drugs or unable to take them orally;Patients who refuse the medication regimen;
- •Serious dysfunction of vital organs (heart, liver, kidney);Clinically significant heart disease, i.e., New York Heart Association (NYHA) grade ⅲ - ⅳ heart failure or more severe congestive heart failure or severe arrhythmias requiring pharmacological intervention;Uncontrollable angina pectoris, uncontrolled arrhythmia or uncontrolled hypertension, myocardial infarction within 6 months as confirmed by electrocardiogram (ECG);Previous history of organ transplantation, splenectomy;
- •Patients with other malignancies, except for cured non-melanoma skin cancers, cervical carcinoma in situ and other tumors that have been cured for at least 5 years;
- •Pregnant and lactating women (women of childbearing age are subject to pregnancy tests), fertile women with positive baseline pregnancy tests, or women of childbearing age who are unwilling to use effective contraception throughout the study period.;
- •In the active period of other acute infectious diseases or chronic infectious diseases;
- •A history of uncontrolled epilepsy, central nervous system disease or mental disorder;
- •Persons with disabilities of consciousness and other legal capacity or legal capacity limited;
- •A known history of human immunodeficiency virus;
- •Other conditions that the investigator considers inappropriate for the patient to participate in the study.
Arms & Interventions
Experimental Arm
Experimental
Trastuzumab and Pyrotinib
Intervention: Trastuzumab and Pyrotinib (Drug)
Outcomes
Primary Outcomes
objective response rate(ORR)
Time Frame: up to 1 year after the last patient enrolled
The ORR will be defined as the proportion of patients in the Efficacy Evaluable patient Set who achieve complete response (CR) and partial response (PR)
Secondary Outcomes
- Progression free survival(PFS)(up to 1 year after the last patient enrolled)
- Incidence and Severity of adverse events(approximately 1.5 years)
Investigators
Peng Yuan
Screening plasma HER2 amplication by Digital PCR in Advanced Breast Cancer Patients Treated With Trastuzumab and Pyrotinib.
Chinese Academy of Medical Sciences
Similar Trials
Not yet recruiting
Not Applicable
Phase II Clinical Study of T-DM1 and Pyrotinib Maleate in Patients With HER2-positive Metastatic Breast Cancer Who Had Progressed on TKI TherapyHER2+ Advanced Breast Cancer Patients Progressing on TKI TherapyNCT05560308Tianjin Medical University Cancer Institute and Hospital50
Recruiting
Phase 2
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast CancerHER2-positive Breast CancerInvasive Carcinoma of the BreastNode Negative Breast CancerMicrometastasis Breast CancerHormone Receptor Positive Breast CancerBreast CancerNCT04569747Dana-Farber Cancer Institute375
Unknown
Phase 2
Neoadjuvant Trastuzumab and Letrozole for Postmenopausal WomenBreast CancerNCT02214004Gangnam Severance Hospital132
Completed
Not Applicable
Trastuzumab incombination with S-1/CDDP of HER2-positive advanced gastric cancer: a phase II trial.HER2 positive gastric cancerJPRN-UMIN000005792Dept. of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences30
Not yet recruiting
Phase 2
Adjuvant Dual Anti-HER2 Therapy in Patients With Small, Node-negative, HER2-positive Breast CancerHER2-positive Breast CancerNCT04158856xuexin he60